Shang Hai Zheng Quan Bao·2025-10-13 18:20Core Insights - He Yuan Bio has developed an innovative technology called "rice blood production" over nearly 20 years, focusing on rice endosperm cell bioreactor technology, which has led to the establishment of efficient recombinant protein expression and purification platforms [2] - The company's core product, recombinant human albumin injection (from rice), was approved for market release in July this year, marking a significant shift from reliance on plasma extraction for such products [2] - He Yuan Bio has secured over 80 invention patents and built an intelligent production line capable of producing 10 tons of raw liquid and 1 million dosage forms annually, establishing a sales network across more than 30 provinces and cities in China [2] - The company is set to begin construction of a new industrial base project in September 2024, which will have an annual production capacity of 120 tons of raw liquid, enhancing its competitive edge in the recombinant human albumin market [2] Industry Context - He Yuan Bio is the first company to pass the review under the fifth set of standards of the Sci-Tech Innovation Board after its restart, highlighting the capital market's support for technological innovation and its adaptability to high-quality tech enterprises [3] - The successful listing of He Yuan Bio on the capital market represents a milestone in its development, indicating the company's entry into a new phase with unlimited potential [3] - The underwriting and sponsorship by Guotai Junan Securities emphasizes the commitment to providing professional services in the capital market, ensuring compliance with relevant regulations during the IPO process [4]